The present disclosure relates generally to the field of medical devices. More particularly, some embodiments relate to medical assemblies and devices for improving blood flow to regions of a patient's body.
The written disclosure herein describes illustrative embodiments that are non-limiting and non-exhaustive. Reference is made to certain of such illustrative embodiments that are depicted in the figures, in which:
Many patients who suffer from kidney malfunction undergo hemodialysis to remove waste products from their blood. Hemodialysis generally requires access to an adequate blood supply. In some cases, access to a blood supply may be established via an arteriovenous fistula. In other circumstances, other methods for accessing the blood supply are used.
For example, in some embodiments, access to a blood supply is established via an arteriovenous graft. In other embodiments, access to a blood supply is established via a graft that extends from a peripheral blood supply to an outlet that is positioned in the central venous system.
Certain embodiments disclosed herein may be used to establish an artificial blood flow path, such as along a non-natural or artificial conduit, that improves or provides alternative access to a blood supply. The artificial flow path may be used, for example, to bypass a central venous stenosis. In some embodiments, the artificial blood flow path, when implanted into a patient, is fully subcutaneous. Access to a blood supply that is provided by an artificial flow path may be particularly advantageous for access in hemodialysis patients (such as hemodialysis patients who have exhausted peripheral venous access sites for fistulas).
The components of the embodiments as generally described and illustrated in the figures herein can be arranged and designed in a wide variety of different configurations. Thus, the following more detailed description of various embodiments, as represented in the figures, is not intended to limit the scope of the present disclosure, but is merely representative of various embodiments. While various aspects of the embodiments are presented in drawings, the drawings are not necessarily drawn to scale unless specifically indicated.
The phrase “coupled to” is broad enough to refer to any suitable coupling or other form of interaction between two or more entities. Thus, two components may be coupled to each other even though they are not in direct contact with each other. For example, two components may be coupled to each other through an intermediate component. The phrase “attached to” refers to interaction between two or more entities which are in direct contact with each other and/or are separated from each other only by a fastener of any suitable variety (e.g., an adhesive). The phrase “fluid communication” is broad enough to refer to arrangements in which a fluid (e.g., blood) can flow from one element to another element when the elements are in fluid communication with each other. Unless otherwise stated, all ranges include both endpoints and all numbers between the endpoints.
The terms “central” and “peripheral,” as used herein, are opposite directional terms along a flow path of the vasculature. For example, a peripheral end of a device or component is the end of the device or component that is furthest from the heart when the device or component is assembled and implanted within the patient. The central end portion refers to the opposite end or the end closest to the heart of the patient when the device is in use. Further, this reference frame is applied herein to devices configured or designed to have one end (a central end) positioned closer to the heart when the device is in use, whether or not the device itself is deployed within the body.
In various embodiments, the first tubular conduit 110 may be resistant to kinking and/or crush forces. The first tubular conduit 110 may be reinforced. For example, the first tubular conduit 110 may be reinforced with nitinol, such as braided nitinol, which can provide resistance to kinking and/or crush forces. More specifically, in various embodiments, the first tubular conduit 110 may include silicone-coated nitinol.
In some embodiments, the first tubular conduit 110 may include one or more radiopaque bands or markers (not shown). For example, the first tubular conduit 110 may include a radiopaque band adjacent the central end portion of the first tubular conduit 110. The radiopaque band(s) or marker(s) may facilitate fluoroscopic placement of the first tubular conduit 110 within a patient.
In certain embodiments, the second tubular conduit 120 may be configured to be accessed for hemodialysis. In other words, during some medical procedures (e.g., hemodialysis), the second tubular conduit 120 may be accessed in lieu of the natural vasculature of a patient. In various embodiments, the second tubular conduit 120 may include and/or consist of polytetrafluoroethylene (PTFE) (e.g., such as expanded PTFE (ePTFE), rotational spun PTFE, or electrospun PTFE). In various other embodiments, the second tubular conduit 120 may include silicone, a fibrous polymer, or another suitable material.
In some embodiments, the second tubular conduit 120 may include a puncturable and self-sealing wall such that the wall may be punctured by insertion of a needle and then reseal upon withdrawal of the needle. The self-sealing wall may be of any suitable composition. In certain embodiments, the self-sealing wall may be a multi-layered construct. For example, the self-sealing wall may include an outer layer, an inner layer, and at least one tie layer disposed between the outer layer and the inner layer. One or more of the outer layer and the inner layer may include PTFE. For example, the outer layer may include and/or consist of expanded PTFE while the inner layer may include and/or consist of rotational spun or electrospun PTFE. The tie layer may include an elastomer such as elastomeric silicone. Due, at least in part, to the properties of the silicone, the resulting construct may be self-sealing. In other words, when a needle that has been inserted through the wall is withdrawn from the second tubular conduit 120, the wall may seal itself, thereby preventing leakage of blood from the second tubular conduit 120.
In various embodiments, the second tubular conduit 120 may have an initial length of at least 30 cm, at least 40 cm, or at least 45 cm. For example, the second tubular conduit 120 may be between about 30 cm and about 70 cm or between about 40 cm and about 60 cm in length. In some embodiments, the second tubular conduit 120 may have an internal diameter of between about 4.5 mm and about 8 mm. For example, the internal diameter of the second tubular conduit 120 may be between about 5.5 mm and about 6.5 mm.
In some embodiments, both the first tubular conduit 110 and the second tubular conduit 120 may be self-sealing. In some other embodiments, only the second tubular conduit 120 may be self-sealing.
In certain embodiments, one or both of an inner surface and an outer surface of the vascular access assembly 100 may be associated with a therapeutic agent. In other words, the therapeutic agent may be disposed on or embedded within a surface of the vascular access assembly 100. The therapeutic agent may be released from the surface(s) of the vascular access assembly 100 to deliver a therapeutically effective dose of the therapeutic agent to the patient when the vascular access assembly 100 is implanted within a patient. In various embodiments, a first therapeutic agent is associated with the inner surface of the vascular access assembly 100 and a second therapeutic agent that differs from the first therapeutic agent is associated with the outer surface of the vascular access assembly 100. In such embodiments, both the first therapeutic agent and the second therapeutic agent may be delivered into the bloodstream of the patient in therapeutically effective doses when the vascular access assembly 100 is implanted within the patient. In some embodiments, heparin may be used as a therapeutic agent. The therapeutic agent may reduce or be configured to reduce thrombus or tissue proliferation.
With continued reference to
As depicted, the connector 122 may include one or more barbs or protrusions 124 that are designed to engage with an inner surface of the first tubular conduit 110 to form a fluid-tight connection. In some embodiments, any attempt to remove the first tubular conduit 110 from the connector 122 may cause the first tubular conduit 110 to “neck down” or become narrower in diameter, thereby causing the first tubular conduit 110 to more tightly engage with the connector 122. While
The vascular access assembly 100 may be used in any suitable medical procedure, such as to establish vascular access for hemodialysis. For example, where a vein has become stenotic or otherwise failed an artificial flow path that bypasses the stenosis or failure may be established. Stated another way, an artificial flow path may be established from a target site (e.g., from a target site in a vessel, artery, arteriovenous graft, etc.) to the vena cava or right atrium of the heart. Various examples herein discuss access and therapies performed in the right atrium of the heart. These examples and related disclosure may be analogously applied to access and therapies performed at adjacent locations such as the vena cava or the venous vasculature around the vena cava. Still further, the assemblies discussed herein may be utilized to create synthetic blood flow paths in other areas of the body as well and disclosure relative to specific examples, such as placement of a device in the right atrium, may be analogously applied to other areas of the body.
As shown in
After the central end portion 112 of the first tubular conduit 110 has been placed within the right atrium of the heart 20, a second incision 4 (see
Once the first tubular conduit 110 has been placed such that the first tubular conduit 110 extends from the right atrium of the heart 20 to the second incision 4 in the shoulder region of the patient 50, an incision may be made at a target site 13, for example, in an artery as depicted. In some other embodiments, the target site 13 may be in an arteriovenous graft, a vein, or another suitable position. A tunneling device may then be used to establish a subcutaneous path between the second incision 4 in the shoulder region of the patient 50 to the target site 13, A peripheral end 128 of the second tubular conduit 120 may then be inserted into the second incision 4 and advanced along the path established by the tunneling device (i.e., the second tubular conduit 120 is tunneled) such that the second tubular conduit 120 extends from the second incision 4 in the shoulder region of the patient 50 to the target site 13 as shown in
With the central end portion 112 of the first tubular conduit 110 disposed within the right atrium of the heart 20 of the patient 50, the peripheral end 114 of the first tubular conduit 110 may then, if needed, be cut to the appropriate length. In other words, the first tubular conduit 110 may initially (e.g., when manufactured and inserted as described above) have a length that is longer than is needed to establish a flow path from the right atrium of the heart 20 of the patient 50 to the second incision 4 in the shoulder region of the patient 50. The first tubular conduit 110 may then be cut to proper length to facilitate coupling of the second tubular conduit 120 to the first tubular conduit 110 at the second incision 4 in the shoulder region of the patient 50. As depicted, the central end 126 of the second tubular conduit 120 may be coupled to the peripheral end 114 of the first tubular conduit 110 via the connector 122.
Similarly, in some embodiments, the second tubular conduit 120 may have an initial length that is longer than is needed to establish a flow path from the second incision 4 in the shoulder region of the patient 50 to the target site 13. In such embodiments, the central end 126 of the second tubular conduit 120 may be cut to the appropriate length once the second tubular conduit 120 has been inserted into the patient 50. In some embodiments, the connector 122 may then be attached to the newly formed central end portion of the second tubular conduit 120. In some other embodiments, no cutting of the second tubular conduit 120 may be needed.
Once the first tubular conduit 110 and the second tubular conduit 120 are the proper length, the second tubular conduit 120 may be coupled to the first tubular conduit 110, or vice versa. For example, the connector 122 at the central end 126 of the second tubular conduit 120 may be inserted into the peripheral end 114 of the first tubular conduit 110 such that the barbs or protrusions 124 of the connector 122 engage with an inner surface of the first tubular conduit 110 (see
The peripheral end 128 of the second tubular conduit 120 may be coupled to an artery at the target site 13. For example, an incision may be made at the target site 13 and an arterial anastomosis may be performed between the peripheral end 128 of the second tubular conduit 120 and the target site 13. Coupling of a portion of the vascular access assembly 100 (e.g., the peripheral end 128 of the second tubular conduit 120) to an artery may be performed via any suitable technique. Once a flow path from the target site 13 to the heart 20 has been established as shown in
The implanted vascular access assembly 100 may be used to facilitate vascular access. For example, in the case of hemodialysis, a practitioner may insert a first needle through the skin of the patient 50 and into the vascular access assembly 100. More particularly, the first needle may be inserted into the second tubular conduit 120. Fluid may be withdrawn from the vascular access assembly 100 and drawn into a dialysis machine that purifies the blood. The purified blood may then be returned to the patient 50 via a second needle that extends through the skin of the patient 50 and into a more central location of the second tubular conduit 120.
The steps of the procedure described above are only exemplary in nature. In other words, the vascular access assembly 100 may be implanted into the patient 50 via a procedure that deviates somewhat from the procedure described above. One of ordinary skill in the art, having the benefit of this disclosure, will also appreciate that some of the steps described above need not be performed in the order that is specified above.
An additional aspect of the disclosure relates to methods of accessing an implanted vascular access assembly 100. A practitioner may desire to access the vascular access assembly 100 so that the practitioner may clean or clear at least a portion of the vascular access assembly 100. In some embodiments, the vascular access assembly 100, or at least a portion of the vascular access assembly 100, may become occluded and/or blocked during use. For example, a blood clot or other embolus may develop within at least a portion of the vascular access assembly 100. Accordingly, the practitioner may access the vascular access assembly 100 to remove the blood clot or other embolus from within the vascular access assembly 100. In an effort to streamline the disclosure, the methods provided herein generally refer to the removal of a blood clot from the vascular access assembly 100. The provided methods, however, may also be used and/or adapted for the removal of other types of emboli from within the vascular access assembly 100 (e.g., fatty deposits, tissue growths, etc.).
In some embodiments, methods of declotting the vascular access assembly 100 may further include decoupling the first tubular conduit 110 and the second tubular conduit 120, for example, at the connector 122. The practitioner may then couple a flushing mechanism (not shown) to the peripheral end 114 of the first tubular conduit 110. The flushing mechanism may be a component of the vascular access assembly declotting system. In certain embodiments, the flushing mechanism may include a flushing catheter, wherein a peripheral end portion of the flushing catheter is in fluid communication with a fluid source (e.g., a source of a saline solution or another suitable fluid). Upon coupling of the flushing mechanism and the first tubular conduit 110, the practitioner may displace a fluid through at least a portion of the flushing mechanism and through at least a portion of the first tubular conduit 110.
In some embodiments, a practitioner may couple a vacuum source to a peripheral end 114 of the first tubular conduit 110. In certain embodiments, the vacuum source may be coupled to the first tubular conduit 110 via a vacuum catheter. In some embodiments, the vacuum source and/or the vacuum catheter may be components of the vascular access assembly declotting system.
The vacuum source may be activated (e.g., by the practitioner) such that a suction force is applied on the first tubular conduit 110 and a clot disposed within the first tubular conduit 110 can be displaced from within, evacuated from, or sucked out of the first tubular conduit 110.
In some embodiments, the first tubular conduit 110 and the second tubular conduit 120 may be decoupled and a low-profile balloon may be fed via a guidewire through either the first tubular conduit 110 or the second tubular conduit 120. The low-profile balloon may be slid through the clot and then inflated and pulled out the respective tubular conduit 110 or 120 via the guidewire to remove the clot.
Preferably, in each of the declotting methods, the first tubular conduit 110 and the second tubular conduit 120 can be decoupled without damage and recoupled once the clot is removed.
Therefore, in some embodiments, the vascular access system includes a releasable connector such that the first tubular conduit 110 and the second tubular conduit 120 may be decoupled to make adjustments to either the first tubular conduit 110 or the second tubular conduit 120 during implantation, after implantation, or to declot, as discussed above, one or the other of the first tubular conduit 110 and the second tubular conduit 120. After adjustments or declotting, the first tubular conduit 110 and the second tubular conduit 120 may be recoupled together without removing or damaging either the first tubular conduit 110 or the second tubular conduit 120.
For example, as seen in
While
The releasable connection portion 202 may be any type of releasable connector that creates a fluid-tight connection between the first tubular conduit 110 and the second tubular conduit 120.
The connector assembly 600 includes a ring structure 608 that extends radially outwardly from a surface of the connector assembly 600. The ring structure 608 may include one or more holes 610. When the second tubular conduit 120 is disposed over the second portion 604, one or more sutures 612 may be threaded through the second tubular conduit 120 and tied to one or more holes 610 of the ring structure 608. To remove the second tubular conduit 120 from the connector assembly 600, the one or more sutures 612 may be cut and the second tubular conduit 120 may be removed from the connector assembly 600 without damage to the second tubular conduit. Although a ring structure 608 is shown in
One member of the first member 802 and the second member 804 is sized to fit within the other member. For example, as seen in
In
To couple the first tubular conduit 110 and the second tubular conduit 120, the end of the second member 804 is engaged with an end of the first member 802. A clamp 808 may then be provided to provide a force between a neck portion 810 of the first member 802 and a neck portion 812 of the second member 804. This prevents the first tubular conduit 110 and the second tubular conduit 120 from separating while implanted and creates a fluid-tighter connection.
Although the connectors in
A T or Y shaped connector, such as connector 900 of
Any methods disclosed herein include one or more steps or actions for performing the described method. The method steps and/or actions may be interchanged with one another. In other words, unless a specific order of steps or actions is required for proper operation of the embodiment, the order and/or use of specific steps and/or actions may be modified. Moreover, sub-routines or only a portion of a method described herein may be a separate method within the scope of this disclosure. Stated otherwise, some methods may include only a portion of the steps described in a more detailed method.
Reference throughout this specification to “an embodiment” or “the embodiment” means that a particular feature, structure, or characteristic described in connection with that embodiment is included in at least one embodiment. Thus, the quoted phrases, or variations thereof, as recited throughout this specification are not necessarily all referring to the same embodiment.
Similarly, it should be appreciated by one of skill in the art with the benefit of this disclosure that in the above description of embodiments, various features are sometimes grouped together in a single embodiment, figure, or description thereof for the purpose of streamlining the disclosure. This method of disclosure, however, is not to be interpreted as reflecting an intention that any claim requires more features than those expressly recited in that claim. Rather, as the following claims reflect, inventive aspects lie in a combination of fewer than all features of any single foregoing disclosed embodiment. Thus, the claims following this Detailed Description are hereby expressly incorporated into this Detailed Description, with each claim standing on its own as a separate embodiment. This disclosure includes all permutations of the independent claims with their dependent claims.
Recitation in the claims of the term “first” with respect to a feature or element does not necessarily imply the existence of a second or additional such feature or element. It will be apparent to those having skill in the art that changes may be made to the details of the above-described embodiments without departing from the underlying principles of the present disclosure.
This application claims priority to U.S. Provisional Application No. 62/532,577, filed on Jul. 14, 2017 and titled “Releasable Conduit Connectors” which is hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3357432 | Sparks | Dec 1967 | A |
3435823 | Edwards | Apr 1969 | A |
3490438 | Lavender et al. | Jan 1970 | A |
3683926 | Suzuki | Aug 1972 | A |
3814137 | Martinez | Jun 1974 | A |
3818511 | Goldberg et al. | Jun 1974 | A |
3826257 | Buselmeier | Jul 1974 | A |
3853126 | Schulte | Dec 1974 | A |
3882862 | Berend | May 1975 | A |
3998222 | Shihata | Dec 1976 | A |
4076023 | Martinez | Feb 1978 | A |
4133312 | Burd | Jan 1979 | A |
4184489 | Burd | Jan 1980 | A |
4214586 | Mericle | Jul 1980 | A |
4318401 | Zimmernan | Mar 1982 | A |
4366819 | Kaster | Jan 1983 | A |
4427219 | Madej | Jan 1984 | A |
4441215 | Kaster | Apr 1984 | A |
4447237 | Frisch et al. | May 1984 | A |
4496349 | Cosentino | Jan 1985 | A |
4496350 | Cosentino | Jan 1985 | A |
4503568 | Madras | Mar 1985 | A |
4517747 | Morin | May 1985 | A |
4550447 | Seiler, Jr. | Nov 1985 | A |
4619641 | Schanzer | Oct 1986 | A |
4655771 | Wallersten | Apr 1987 | A |
4723948 | Clark et al. | Feb 1988 | A |
4734094 | Jacob et al. | Mar 1988 | A |
4753236 | Healy | Jun 1988 | A |
4771777 | Horzewski et al. | Sep 1988 | A |
4772268 | Bates | Sep 1988 | A |
4786345 | Wood | Nov 1988 | A |
4790826 | Elftman | Dec 1988 | A |
4822341 | Colone | Apr 1989 | A |
4848343 | Wallsten et al. | Jul 1989 | A |
4850999 | Planck | Jul 1989 | A |
4877661 | House et al. | Oct 1989 | A |
4898591 | Jang et al. | Feb 1990 | A |
4898669 | Tesio | Feb 1990 | A |
4917087 | Walsh et al. | Apr 1990 | A |
4919127 | Pell | Apr 1990 | A |
4929236 | Sampson | May 1990 | A |
4955899 | Della Corna et al. | Sep 1990 | A |
5026513 | House et al. | Jun 1991 | A |
5041098 | Loiterman et al. | Aug 1991 | A |
5042161 | Hodge | Aug 1991 | A |
5053023 | Martin | Oct 1991 | A |
5061275 | Wallsten et al. | Oct 1991 | A |
5061276 | Tu et al. | Oct 1991 | A |
5064435 | Porter | Nov 1991 | A |
5104402 | Melbin | Apr 1992 | A |
5171227 | Twardowski et al. | Dec 1992 | A |
5171305 | Schickling et al. | Dec 1992 | A |
5192289 | Jessen | Mar 1993 | A |
5192310 | Herweck et al. | Mar 1993 | A |
5197976 | Herweck et al. | Mar 1993 | A |
5251642 | Handlos | Oct 1993 | A |
5282860 | Matsuno et al. | Feb 1994 | A |
5330500 | Song | Jul 1994 | A |
5336616 | Livesey et al. | Aug 1994 | A |
5353513 | Round | Oct 1994 | A |
5399168 | Wadsworth | Mar 1995 | A |
5405320 | Twardowski et al. | Apr 1995 | A |
5405339 | Kohnen et al. | Apr 1995 | A |
5454790 | Dubrul | Oct 1995 | A |
5474268 | Yu | Dec 1995 | A |
5474563 | Myler et al. | Dec 1995 | A |
5476451 | Ensminger et al. | Dec 1995 | A |
5496294 | Hergenrother et al. | Mar 1996 | A |
5509897 | Twardowski et al. | Apr 1996 | A |
5549663 | Cottone, Jr. | Aug 1996 | A |
5558641 | Glantz et al. | Sep 1996 | A |
5562617 | Finch, Jr. et al. | Oct 1996 | A |
5562618 | Cai et al. | Oct 1996 | A |
5591226 | Trerotola et al. | Jan 1997 | A |
5607463 | Schwartz et al. | Mar 1997 | A |
5624413 | Markel et al. | Apr 1997 | A |
5637088 | Wenner et al. | Jun 1997 | A |
5637102 | Tolkoff et al. | Jun 1997 | A |
5645532 | Horgan | Jul 1997 | A |
5647855 | Frooskin | Jul 1997 | A |
5669637 | Chitty et al. | Sep 1997 | A |
5669881 | Dunshee | Sep 1997 | A |
5674272 | Bush et al. | Oct 1997 | A |
5676346 | Leinsing | Oct 1997 | A |
5743894 | Swisher | Apr 1998 | A |
5755773 | Schuster | May 1998 | A |
5755775 | Trerotola et al. | May 1998 | A |
5792104 | Speckman et al. | Aug 1998 | A |
5797879 | Decampli | Aug 1998 | A |
5800512 | Lentz et al. | Sep 1998 | A |
5800514 | Nunez et al. | Sep 1998 | A |
5800522 | Campbell | Sep 1998 | A |
5810870 | Myers et al. | Sep 1998 | A |
5830224 | Cohn et al. | Nov 1998 | A |
5840240 | Stenoien et al. | Nov 1998 | A |
5866217 | Stenoien et al. | Feb 1999 | A |
5904967 | Ezaki et al. | May 1999 | A |
5931829 | Burbank et al. | Aug 1999 | A |
5931865 | Silverman et al. | Aug 1999 | A |
5957974 | Thompson et al. | Sep 1999 | A |
5997562 | Zadno-Azizi | Dec 1999 | A |
6001125 | Golds et al. | Dec 1999 | A |
6019788 | Butters et al. | Feb 2000 | A |
6036724 | Lentz et al. | Mar 2000 | A |
6102884 | Squitieri | Aug 2000 | A |
6156016 | Maginot | Dec 2000 | A |
6167765 | Weitzel | Jan 2001 | B1 |
6171295 | Garabedian | Jan 2001 | B1 |
6231085 | Olson | May 2001 | B1 |
6245098 | Feeser | Jun 2001 | B1 |
6255396 | Ding et al. | Jul 2001 | B1 |
6261255 | Mullis et al. | Jul 2001 | B1 |
6261257 | Uflacker et al. | Jul 2001 | B1 |
6280466 | Kugler et al. | Aug 2001 | B1 |
6308992 | Mitsui et al. | Oct 2001 | B1 |
6309411 | Lashinski et al. | Oct 2001 | B1 |
6319279 | Shannon et al. | Nov 2001 | B1 |
6338724 | Dossa | Jan 2002 | B1 |
6398764 | Finch, Jr. et al. | Jun 2002 | B1 |
6402767 | Nash et al. | Jun 2002 | B1 |
6428571 | Lentz et al. | Aug 2002 | B1 |
6436132 | Patel et al. | Aug 2002 | B1 |
6582409 | Squitieri | Jun 2003 | B1 |
6585762 | Stanish | Jul 2003 | B1 |
6610004 | Viole et al. | Aug 2003 | B2 |
6689096 | Loubens et al. | Feb 2004 | B1 |
6689157 | Madrid et al. | Feb 2004 | B2 |
6692461 | Wantink | Feb 2004 | B2 |
6699233 | Slanda et al. | Mar 2004 | B2 |
6702748 | Nita et al. | Mar 2004 | B1 |
6702781 | Reifart et al. | Mar 2004 | B1 |
6706025 | Engelson et al. | Mar 2004 | B2 |
6719781 | Kim | Apr 2004 | B1 |
6719783 | Lentz et al. | Apr 2004 | B2 |
6730096 | Basta | May 2004 | B2 |
6733459 | Atsumi | May 2004 | B1 |
6740273 | Lee | May 2004 | B2 |
6749574 | O'Keefe | Jun 2004 | B2 |
6752826 | Holloway et al. | Jun 2004 | B2 |
6758836 | Zawacki | Jul 2004 | B2 |
6858019 | McGuckin, Jr. et al. | Feb 2005 | B2 |
6926724 | Chu | Aug 2005 | B1 |
6926735 | Henderson | Aug 2005 | B2 |
6976952 | Maini et al. | Dec 2005 | B1 |
6981987 | Huxel et al. | Jan 2006 | B2 |
7011645 | McGuckin, Jr. et al. | Mar 2006 | B2 |
7025741 | Cull | Apr 2006 | B2 |
7036599 | Matteucci | May 2006 | B2 |
7044937 | Kirwan et al. | May 2006 | B1 |
7101356 | Miller | Sep 2006 | B2 |
7131959 | Blatter | Nov 2006 | B2 |
7211074 | Sansoucy | May 2007 | B2 |
7244271 | Lenz et al. | Jul 2007 | B2 |
7244272 | Dubson et al. | Jul 2007 | B2 |
7252649 | Sherry | Aug 2007 | B2 |
7297158 | Jensen | Nov 2007 | B2 |
7351257 | Kaldany | Apr 2008 | B2 |
7399296 | Poole et al. | Jul 2008 | B2 |
7438699 | Pecor et al. | Oct 2008 | B2 |
7452374 | Hain et al. | Nov 2008 | B2 |
7507229 | Hewitt et al. | Mar 2009 | B2 |
7588551 | Gertner | Sep 2009 | B2 |
7708722 | Glenn | May 2010 | B2 |
7722665 | Anwar et al. | May 2010 | B2 |
RE41448 | Squitieri | Jul 2010 | E |
7762977 | Porter | Jul 2010 | B2 |
7789908 | Sowinski et al. | Sep 2010 | B2 |
7828833 | Haverkost et al. | Nov 2010 | B2 |
7833214 | Wilson et al. | Nov 2010 | B2 |
7846139 | Zinn et al. | Dec 2010 | B2 |
7850675 | Bell et al. | Dec 2010 | B2 |
7850705 | Bachinski et al. | Dec 2010 | B2 |
7922757 | McGuckin | Apr 2011 | B2 |
7972314 | Bizup et al. | Jul 2011 | B2 |
8079973 | Herrig et al. | Dec 2011 | B2 |
8092435 | Beling et al. | Jan 2012 | B2 |
8097311 | Wang et al. | Jan 2012 | B2 |
8313524 | Edwin et al. | Nov 2012 | B2 |
8388634 | Rubenstein et al. | Mar 2013 | B2 |
8512312 | Sage | Aug 2013 | B2 |
8551139 | Surti et al. | Oct 2013 | B2 |
8690815 | Porter et al. | Apr 2014 | B2 |
8951355 | Boyle, Jr. et al. | Feb 2015 | B2 |
9642623 | Agarwal et al. | May 2017 | B2 |
9731113 | Grace et al. | Aug 2017 | B2 |
10172673 | Viswanathan et al. | Jan 2019 | B2 |
20010053930 | Kugler et al. | Dec 2001 | A1 |
20020049403 | Alanis | Apr 2002 | A1 |
20020055766 | Wallace et al. | May 2002 | A1 |
20020055771 | Sandock | May 2002 | A1 |
20020069893 | Kawazoe | Jun 2002 | A1 |
20020099432 | Yee | Jul 2002 | A1 |
20020151761 | Viole et al. | Oct 2002 | A1 |
20030100859 | Henderson et al. | May 2003 | A1 |
20030131489 | Hsiao | Jul 2003 | A1 |
20030135258 | Andreas et al. | Jul 2003 | A1 |
20030135261 | Kugler et al. | Jul 2003 | A1 |
20030139806 | Haverkost et al. | Jul 2003 | A1 |
20030181969 | Kugler et al. | Sep 2003 | A1 |
20030212385 | Brenner et al. | Nov 2003 | A1 |
20030212431 | Brady et al. | Nov 2003 | A1 |
20040024442 | Sowinkski et al. | Feb 2004 | A1 |
20040054405 | Thierry et al. | Mar 2004 | A1 |
20040073282 | Stanish | Apr 2004 | A1 |
20040078071 | Escamilla et al. | Apr 2004 | A1 |
20040092956 | Liddicoat et al. | May 2004 | A1 |
20040099395 | Wang et al. | May 2004 | A1 |
20040147866 | Blatter et al. | Jul 2004 | A1 |
20040193242 | Lentz et al. | Sep 2004 | A1 |
20040215058 | Zirps et al. | Oct 2004 | A1 |
20040215337 | Hain et al. | Oct 2004 | A1 |
20040236412 | Brar | Nov 2004 | A1 |
20050004553 | Douk | Jan 2005 | A1 |
20050137614 | Porter | Jun 2005 | A1 |
20050192559 | Michels et al. | Sep 2005 | A1 |
20050203457 | Smego | Sep 2005 | A1 |
20050209581 | Butts et al. | Sep 2005 | A1 |
20050215938 | Khan et al. | Sep 2005 | A1 |
20060004392 | Amarant | Jan 2006 | A1 |
20060029465 | Auer | Feb 2006 | A1 |
20060058867 | Thistle et al. | Mar 2006 | A1 |
20060064159 | Porter et al. | Mar 2006 | A1 |
20060081260 | Eells et al. | Apr 2006 | A1 |
20060118236 | House et al. | Jun 2006 | A1 |
20070038288 | Lye et al. | Feb 2007 | A1 |
20070078412 | McGuckin, Jr. et al. | Apr 2007 | A1 |
20070078416 | Eliasen | Apr 2007 | A1 |
20070078438 | Okada | Apr 2007 | A1 |
20070088336 | Dalton | Apr 2007 | A1 |
20070123811 | Squitieri | May 2007 | A1 |
20070135775 | Edoga et al. | Jun 2007 | A1 |
20070142850 | Fowler | Jun 2007 | A1 |
20070161958 | Glenn | Jul 2007 | A1 |
20070167901 | Herrig et al. | Jul 2007 | A1 |
20070168019 | Amplatz et al. | Jul 2007 | A1 |
20070173868 | Bachinski et al. | Jul 2007 | A1 |
20070179513 | Deutsch | Aug 2007 | A1 |
20070191779 | Shubayev et al. | Aug 2007 | A1 |
20070197856 | Gellman et al. | Aug 2007 | A1 |
20070213838 | Hengelmolen | Sep 2007 | A1 |
20070219510 | Zinn et al. | Sep 2007 | A1 |
20070233018 | Bizup et al. | Oct 2007 | A1 |
20070249986 | Smego | Oct 2007 | A1 |
20070249987 | Gertner | Oct 2007 | A1 |
20070265584 | Hickman et al. | Nov 2007 | A1 |
20070293823 | Sherry | Dec 2007 | A1 |
20070293829 | Conlon et al. | Dec 2007 | A1 |
20080009781 | Anwar et al. | Jan 2008 | A1 |
20080027534 | Edwin et al. | Jan 2008 | A1 |
20080132924 | McGuckin | Jun 2008 | A1 |
20080167595 | Porter et al. | Jul 2008 | A1 |
20080221469 | Shevchuk | Sep 2008 | A1 |
20080267688 | Busted | Oct 2008 | A1 |
20080306580 | Jenson et al. | Dec 2008 | A1 |
20090076587 | Cully et al. | Mar 2009 | A1 |
20090137944 | Haarala et al. | May 2009 | A1 |
20090179422 | Werth | Jul 2009 | A1 |
20090227932 | Herrig | Sep 2009 | A1 |
20090234267 | Ross | Sep 2009 | A1 |
20090318895 | Lachner | Dec 2009 | A1 |
20100154800 | Chang et al. | Jun 2010 | A1 |
20100160847 | Braido et al. | Jun 2010 | A1 |
20100161040 | Braido et al. | Jun 2010 | A1 |
20100198079 | Ross | Aug 2010 | A1 |
20100268188 | Hanson | Oct 2010 | A1 |
20100268196 | Hastings et al. | Oct 2010 | A1 |
20100292774 | Shalev | Nov 2010 | A1 |
20110015723 | Batiste et al. | Jan 2011 | A1 |
20110054312 | Bell et al. | Mar 2011 | A1 |
20110060264 | Porter et al. | Mar 2011 | A1 |
20110106019 | Bagwell et al. | May 2011 | A1 |
20110112482 | Redd | May 2011 | A1 |
20110196282 | Kassab | Aug 2011 | A1 |
20110208218 | Ball | Aug 2011 | A1 |
20110257609 | Bizup et al. | Oct 2011 | A1 |
20110264080 | Lim et al. | Oct 2011 | A1 |
20110295181 | Dann et al. | Dec 2011 | A1 |
20120059305 | Akingba | Mar 2012 | A1 |
20120065652 | Cully et al. | Mar 2012 | A1 |
20120078202 | Beling et al. | Mar 2012 | A1 |
20130060268 | Herrig | Mar 2013 | A1 |
20130338559 | Franano et al. | Dec 2013 | A1 |
20140018721 | Gage et al. | Jan 2014 | A1 |
20140094841 | Sutton et al. | Apr 2014 | A1 |
20140150782 | Vazales et al. | Jun 2014 | A1 |
20140155908 | Rosenblath et al. | Jun 2014 | A1 |
20140257244 | Johnston et al. | Sep 2014 | A1 |
20140276215 | Nelson | Sep 2014 | A1 |
20140288638 | Knight et al. | Sep 2014 | A1 |
20140296822 | Chartrand | Oct 2014 | A1 |
20140371779 | Vale et al. | Dec 2014 | A1 |
20150051532 | Tomko et al. | Feb 2015 | A1 |
20150082604 | Cully et al. | Mar 2015 | A1 |
20150094744 | Aghayev et al. | Apr 2015 | A1 |
20150150640 | Boyle et al. | Jun 2015 | A1 |
20150165496 | Moreau | Jun 2015 | A1 |
20150257775 | Gilvarry et al. | Sep 2015 | A1 |
20160066954 | Miller et al. | Mar 2016 | A1 |
20160120673 | Siegel et al. | May 2016 | A1 |
20160129177 | Herrig | May 2016 | A1 |
20160136398 | Heilman et al. | Jun 2016 | A1 |
20170020556 | Sutton et al. | Jan 2017 | A1 |
20170106128 | Bagwell et al. | Apr 2017 | A1 |
20190022368 | Hall et al. | Jan 2019 | A1 |
Number | Date | Country |
---|---|---|
4418910 | Dec 1995 | DE |
29515546 | Mar 1997 | DE |
102008055587 | Aug 2009 | DE |
0540834 | May 1993 | EP |
1797831 | Jun 2007 | EP |
5714358 | Jan 1982 | JP |
62112567 | May 1987 | JP |
04507050 | Dec 1992 | JP |
05212107 | Aug 1993 | JP |
06105798 | Apr 1994 | JP |
0984871 | Mar 1997 | JP |
09264468 | Jul 1997 | JP |
2003501223 | Jan 2003 | JP |
3995057 | Oct 2007 | JP |
2008511414 | Apr 2008 | JP |
101026933 | Apr 2011 | KR |
1020110036848 | Apr 2011 | KR |
198403036 | Aug 1984 | WO |
1990085509 | Aug 1990 | WO |
199519200 | Jul 1995 | WO |
199523553 | Sep 1995 | WO |
199624399 | Aug 1996 | WO |
1998034676 | Aug 1998 | WO |
2000027299 | May 2000 | WO |
200076577 | Dec 2000 | WO |
200105447 | Jan 2001 | WO |
200105463 | Jan 2001 | WO |
2001005463 | Jan 2001 | WO |
2001028456 | Apr 2001 | WO |
200238198 | May 2002 | WO |
2004032991 | Apr 2004 | WO |
2004112880 | Dec 2004 | WO |
2006026687 | Sep 2006 | WO |
2007061787 | May 2007 | WO |
2009059371 | May 2009 | WO |
2009082513 | Jul 2009 | WO |
2009120400 | Oct 2009 | WO |
2010059102 | May 2010 | WO |
2011060386 | May 2011 | WO |
2011153302 | Dec 2011 | WO |
2015023460 | Feb 2015 | WO |
2015100251 | Jul 2015 | WO |
2018164945 | Sep 2018 | WO |
Entry |
---|
Office Action dated Aug. 21, 2019 for U.S. Appl. No. 14/192,567. |
International Search Report and Written Opinion dated Jan. 18, 2019 for PCT/US2018/041821. |
Office Action dated Apr. 16, 2020 for U.S. Appl. No. 15/868,313. |
Office Action dated Apr. 28, 2020 for U.S. Appl. No. 14/192,567. |
Office Action dated Sep. 26, 2019 for U.S. Appl. No. 15/693,010. |
Office Action dated May 1, 2020 for U.S. Appl. No. 15/693,010. |
Office Action dated May 5, 2020 for U.S. Appl. No. 15/910,273. |
European Search Report dated Jul. 24, 2020 for EP18738538.0. |
European Search Report dated Jun. 8, 2005 for EP05006233.0. |
European Search Report dated Dec. 3, 2013 for EP05793066.1. |
International Preliminary Report dated Mar. 12, 2014 for PCT/US2012/053967. |
International Search Report and Written Opinion dated Jan. 28, 2015 for PCT/US2014/049547. |
International Search Report and Written Opinion dated Mar. 15, 2013 for PCT/US2012/053967. |
International Search Report and Written Opinion dated Mar. 16, 2015 for PCT/US2014/046630. |
International Search Report and Written Opinion dated May 2, 2018 for PCT/US2018/013326. |
International Search Report and Written Opinion dated May 3, 2013 for PCT/US2012/053967. |
International Search Report and Written Opinion dated May 6, 1998 for PCT/US1998/001939. |
International Search Report and Written Opinion dated Jun. 3, 2009 for PCT/US2009/035923. |
International Search Report and Written Opinion dated Jun. 20, 2007 for PCT/US2006/044564. |
International Search Report and Written Opinion dated Jun. 22, 2018 for PCT/US2018/014371. |
Notice of Allowance dated Mar. 15, 2010 for U.S. Appl. No. 11/216,536. |
Notice of Allowance dated Oct. 4, 2013 for U.S. Appl. No. 12/831,092. |
Office Action dated Jan. 9, 2018 for U.S. Appl. No. 14/450,468. |
Office Action dated Feb. 6, 2013 for U.S. Appl. No. 12/831,092. |
Office Action dated Feb. 21, 2017 for U.S. Appl. No. 14/192,567. |
Office Action dated Mar. 15, 2018 for U.S. Appl. No. 14/332,091. |
Office Action dated May 5, 2010 for U.S. Appl. No. 10/962,200. |
Office Action dated May 24, 2018 for U.S. Appl. No. 14/995,270. |
Office Action dated Jun. 4, 2018 for U.S. Appl. No. 14/192,567. |
Office Action dated Jun. 9, 2016 for U.S. Appl. No. 14/192,567. |
Office Action dated Jun. 15, 2017 for U.S. Appl. No. 14/192,567. |
Office Action dated Jul. 11, 2018 for U.S. Appl. No. 14/450,468. |
Office Action dated Aug. 7, 2017 for U.S. Appl. No. 14/450,468. |
Office Action dated Aug. 12, 2010 for U.S. Appl. No. 10/962,200. |
Office Action dated Aug. 15, 2016 for U.S. Appl. No. 14/332,091. |
Office Action dated Sep. 20, 2012 for U.S. Appl. No. 12/831,092. |
Office Action dated Oct. 27, 2015 for U.S. Appl. No. 14/192,567. |
Office Action dated Nov. 26, 2007 for U.S. Appl. No. 10/962,200. |
Office Action dated Dec. 5, 2017 for U.S. Appl. No. 14/995,270. |
Office Action dated Dec. 20, 2017 for U.S. Appl. No. 14/192,567. |
Office Action dated Dec. 30, 2016 for U.S. Appl. No. 14/450,468. |
Clinical Reveiw of MTI, Onxy Liquid Embolization System, available at http://www.fda.gov/ohrms/dockets/ac/03/briefing/3975b1-02-clinical-review pdf. accessed Aug. 29, 2005. |
Besarab, et al.,Measuring the Adequacy of Hemodialysis Access, Current Opinion in Nephrology and Hypertension, Rapid Science Publishers ISSN ,1996 ,1062-4821. |
Coulson MD, et al.,Modification of Venous End of Dialysis Grafts: An Attempt to Reduce Neointimal Hyperplasia, Dialysis & Transplantation, vol. 29 No. 1 ,Jan. 2000 ,10-18. |
Coulson MD, PhD, et al.,A Combination of the Elephant Trunk Anastomosis Technique and Vascular Clips for Dialysis Grafts, Surgical Rounds ,Nov. 1999 ,596-608. |
Kanterman, et al.,Dialysis Access Grafts: Anatomic Location of Venous Stenosis and Results of Angioplasty, Interventional Radiology, vol. 195 No. 1, 195 ,Apr. 1995 ,135-139. |
Kumpe, et al.,Angioplasty/Thrombolytic Treatment of Failing and Failed Hemodialysis Access Sites: Comparison with Surgical Treatment, Progress in Cardiovascular Diseases, vol. XXXIV No. 4 ,Jan./Feb. 1992 ,263-278. |
Lin, et al.,Contemporary Vascular Access Surgery for Chronic Haemodialysis, They Royal College of Surgeons of Edinburgh, J.R. Coll, Surg, Edinb., 41 ,Jun. 1996 ,164-169. |
Peterson, et al.,Subclavian Venous Stenosis: A Complication of Subclavian Dialysis, The Journal of American Medical Association, vol. 252 No. 24 ,Dec. 28, 1994 ,3404-3406. |
Raju M.D., et al.,Techniques for Insertion and Management of Complications, PTFE Grafts for Hemodialysis Access, Ann. Surg., vol. 206 No. 5 ,Nov. 1987 ,666-673. |
Sharafuddin, et al.,Percutaneous Balloon-Assisted Aspiration Thrombectomy of clotted ahemodialysis Access Grafts, Journal of Vascular and Interventional Radiology, vol. 7 No 2 ,Mar.-Apr. 1996 ,177-183. |
International Search Report and Written Opinion dated Jun. 15, 2018 for PCT/US2018/020614. |
International Search Report and Written Opinion dated Jul. 17, 2018 for PCT/US2018/023956. |
International Search Report and Written Opinion dated Oct. 30, 2018 for PCT/US2018/042900. |
Notice of Allowance dated Oct. 5, 2018 for U.S. Appl. No. 15/093,622. |
Notice of Allowance dated Nov. 6, 2018 for U.S. Appl. No. 14/995,270. |
Office Action dated Jan. 8, 2019 for U.S. Appl. No. 15/035,626. |
Office Action dated Jul. 19, 2018 for U.S. Appl. No. 15/035,626. |
Office Action dated Oct. 1, 2018 for U.S. Appl. No. 14/332,091. |
Office Action dated Dec. 5, 2018 for U.S. Appl. No. 14/450,468. |
Office Action dated Dec. 7, 2018 for U.S. Appl. No. 14/192,567. |
European Search Report dated Oct. 26, 2020 for EP18738538.0. |
Office Action dated Oct. 1, 2020 for U.S. Appl. No. 15/868,313. |
European Search Report dated Dec. 4, 2020 for 18764826.6. |
Office Action dated Nov. 30, 2020 for U.S. Appl. No. 15/910,273. |
European Search Report dated Mar. 22, 2021 for EP18832124.4. |
Notice of Allowance dated Mar. 24, 2021 for U.S. Appl. No. 15/910,273. |
Number | Date | Country | |
---|---|---|---|
20190015627 A1 | Jan 2019 | US |
Number | Date | Country | |
---|---|---|---|
62532577 | Jul 2017 | US |